This suggests that even in highly aggressive conditions, such as multifocal glioblastoma, the presence of certain mutations, such as BRAF p.Val600Glu (V600E)​​​​​​​, could favorably influence tumor behavior and open the door to personalized treatment options. This evidence concerns the gene BRAF and glioblastoma.